October 20, 2020 | COVID-19 Briefings

COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

CMS Sends Cease and Desist Letters to 171 Clinical Laboratories Without Correct CLIA Certification

Rollout and availability of rapid SARS-CoV-2 antigen tests opens wave of CLIA certification issues triggering CMS cease and desist letters.